Neuphoria Therapeutics Inc. Ordinary Shares NEUP 深 滬
等待開盤 10-29 09:30:00 美东时间
4.82
+0.290
+6.40%
華盛通- 最 高5.09
- 今 開4.76
- 成交量 67.99万股
- 最 低 4.6798
- 昨 收 4.53
- 總市值 906.16万
- 52周最高 21.4004
- 市盈率 靜 --
- 換手率 36.17%
- 52周最低 2.90
- 委 比 18.83%
- 總股本 188.00万
- 歷史最高 21.4004
- 量 比 0.07
- 振 幅 9.06%
- 歷史最低 2.90
- 每 手 1
- 風險率 3.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan To Protect Integrity Of Process; Board Declares Dividend Of One Preferred Share Purchase Right For Each Outstanding Share Of Co
Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders,today announced that its Board of Directors
10-28 04:53
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
Neuphoria Therapeutics announced its Board has adopted a limited-duration stockholder rights plan to safeguard against rapid accumulation of its shares by investors. The plan aims to protect shareholder interests, ensure fair participation in strategic reviews, and prevent control without a premium. It does not hinder the Board from exploring strategic alternatives. The rights will trigger if any entity gains 15% ownership without Board approval,...
10-27 20:29
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
10-21 05:08
Neuphoria's AFFIRM-1 Trial For Social Anxiety Fails To Meet Endpoints; Company Initiates Strategic Review
AFFIRM-1 trial did not meet primary endpoint or secondary endpointsCompany to conduct strategic review of portfolio and business operationsBURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc.
10-21 04:19
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
Neuphoria Therapeutics Inc. announced that its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder (SAD) did not meet its primary or secondary endpoints. The company plans to discontinue further development of the SAD program and evaluate next steps for BNC210 in post-traumatic stress disorder (PTSD). Neuphoria will conduct a strategic review of its operations and portfolio. The company has $14.2 million in cash and expects to f...
10-20 20:15
SLING TV UNVEILS "STREAM TEAM" LINEUP: 10 COLLEGE FOOTBALL PLAYERS SIGNED TO $4.99 NIL DEALS
Sling's new $4.99 Day Pass fuels a first-of-its-kind NIL movement proving streaming value beats streaming hype ENGLEWOOD, Colo., Sept. 12, 2025 /PRNewswire/ -- Sling TV, the most flexible li...
09-12 18:00
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
Maxim Group Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $35
Maxim Group analyst Jason McCarthy maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $18 to $35.
09-11 22:30
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
Neuphoria Therapeutics announced the achievement of 332 participants in the AFFIRM-1 Phase 3 trial for BNC-210, a breakthrough acute treatment for social anxiety disorder (SAD). BNC-210, designed to rapidly alleviate anxiety without sedation or cognitive impairment, has received FDA Fast Track designation. The trial evaluates its safety and efficacy through a public speaking challenge and uses multiple metrics to measure anxiety reduction. With t...
09-04 11:00
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Neuphoria Therapeutics Inc. announced that its CEO, Spyros Papapetropoulos, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York. The presentation will be available online starting September 5. Neuphoria, a clinical-stage biotech company, is developing therapies for neuropsychiatric disorders, including its lead drug candidate, BNC-210, for the treatment of social anxiety disorder and P...
08-28 20:05
